Ranibizumab 0.5 mg/0.05 ml

DRUG2 trials

Sponsors

Department of ophthalmology of nihon university hospital, Novartis Pharmaceuticals

Conditions

Central Retinal Vein OcclusionCentral retinal vein occlusionMacular Edema

Phase 2

Intravitreal ranibizumab for the treatment of cystoid macular edema in central retinal vein occlusion with good visual acuity by PRN, phase 2 trial.

Active, not recruitingJPRN-UMIN000015826

Department of ophthalmology of nihon university hospitalCentral retinal vein occlusion

Start: 2014-12-03Target: 20Updated: 2026-06-29

Phase 3

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

CompletedNCT01535261

Novartis PharmaceuticalsCentral Retinal Vein Occlusion, Macular Edema

Start: 2012-02-29End: 2015-03-31Updated: 2016-10-27